TF is a *bona fide* secretory pathway chaperone and interacts with SecB and the translocase

Jozefien De Geyter*, Athina G. Portaliou*, Bindu Srinivasu, Srinath Krishnamurthy, Anastassios Economou** and Spyridoula Karamanou**

KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Molecular Bacteriology, B-3000 Leuven, Belgium.

* Equal contribution
**For correspondence: lily.karamanou@kuleuven.be; tassos.economou@kuleuven.be

Keywords: protein secretion; Sec system; SecA; targeting; chaperone; trigger factor; SecB; Outer Membrane Protein A; translocation-competence; protein complex; preprotein; post-translational network

Table of contents

Appendix Figures

- **Appendix Figure S1**. Apparent K_d of TF dimerization, solubility of proOmpA after pre-incubation times and linear sequence of proOmpA* (related to Figures 1 and 2)……….. *p. 3*
- **Appendix Figure S2**. Native-MS of TF_2 and TF:proOmpA (Related to Figure 2)……..… *p. 4*
- **Appendix Figure S3**. Quantification of SDS-PAGE gels and native-PAGE analyses of TF and SecB interactions and derived SecB-proOmpA affinity (related to Figures 2 and 4) ……………………………………………………………………………………………..… *p. 5*
- **Appendix Figure S4**. ITC analysis of the interaction between TF and either SecB, or SecA wt or SecA(noC-tail)(related to Figures 5 and 6)…………………………………………….… *p. 7*
- **Appendix Figure S5**. Native MS of $SecB_4$ and SecB:proOmpA (related to Figures 4 and 5) ………………………………………………………………………………………………… *p. 8*
- **Appendix Figure S6**. The C-tail of SecA is not required for TF-mediated inhibition of translocation *in vivo* and proOmpA translocation and chaperone interaction is chaotrope-independent (related to Figure 6) …………………………………...…………………… *p. 9*

Appendix Tables:

- **Appendix Table S1**: Bacterial strains …………………..…………………………………….. *p. 10*
- **Appendix Table S2:** Plasmids ……………………………….……………………….... *p. 10*
- **Appendix Table S3:** Primers ………………………..………….…………………..……... *p. 12*
- **Appendix Table S4:** Buffers …………………………………...…………….....…….. *p. 12*



Appendix Figure S1. Apparent K_d of TF dimerization, solubility of proOmpA after pre-incubation times and linear sequence of proOmpA* (related to Figures 1 and 2).

A. Apparent K_d of TF dimerization in solution. The molecular mass of TF was measured using SEC-MALS at the indicated concentration range. Data were plotted using Graph-Pad Prism and the K_d was determined using non-linear regression analysis; *n=1* biological replicate

B. Linear sequence of proOmpA (P0A910) and the proOmpA*derivative. Mutated amino acids indicated in red, (-) amino acid insertion. All mutations and additions reside in the C-terminal periplasmic peptidoglycan-binding domain of proOmpA.

C. proOmpA is retained soluble and does not aggregate at 37°C. $proOmpA_1$ (1 μM) was incubated (Buffer C; < 0.2 M urea; 37°C) as indicated and soluble proteins (harvested after centrifugation; 20,000 x g; 10 min; 4°C) were estimated using Bradford assay (Biorad). The soluble proOmpA remaining in different time points is expressed as a percentage of the input. *n*= 4 biological replicates; mean values ± SEM are shown.





Appendix Figure S2. Native-MS of TF_2 and TF:proOmpA (Related to Fig. 2).

A. TF_2 native-MS analysis at 37°C**.** ESI-mass spectrum and charge state distributions of monomeric (TF_1) and dimeric (TF_2) populations (orange and pink respectively). The deconvoluted mass spectra of native TF_2 are shown (TF_1: 49497.0; Da TF_2:99467.5 Da). Representative experiment is shown; *n=3* biological replicates

B. TF:proOmpA native-MS analysis at 37oC. ESI-mass spectrum and charge state distributions of different protein populations are shown: proOmpA, (TF: proOmpA)$_1$, TF_1 and (TF: proOmpA)$_2$ are colored in cyan, light blue, orange and green respectively. The deconvoluted mass spectra from different populations of the complexes and the derived stoichiometries are shown (cartoon representation). A representative experiment is shown; *n=3* biological replicates



Appendix Figure S3. Quantification of SDS-PAGE gels and native-PAGE analyses of TF and SecB interactions and derived SecB-proOmpA affinity (related to Figures 2 and 4).

A. Quantification of TF: proOmpA complex formed. Signal intensities from Fig. 2A were quantified using Image J software (https://imagej.nih.gov/ij/) and expressed as a percentage of the maximum complex-intensity measured (lane 8); mean values with SEM are shown; *n=4* biological replicates

B. TF rescues proOmpA* from aggregation. Signal intensities from Fig. 2C were quantified using Image J software (https://imagej.nih.gov/ij/) and expressed as percentage of maximum

proOmpA*-intensity measured (lane 9); mean values with SEM are shown; *n=4* biological replicates

C. SecB rescues proOmpA* from aggregation Signal intensities from Fig. 4B were analyzed as in B; mean values with SEM are shown; *n=4* biological replicates

D. Apparent K_d determination of SecB: proOmpA interaction. Signal intensities from Fig. 4C were quantified using Image J software (https://imagej.nih.gov/ij/) and data were plotted on Graph Pad Prism 5.0 as a function of the total concentration of SecB used. *Apparent* K_d was determined after non-linear regression analysis. Mean values with SEM are shown; *n=6* biological replicates

E. TF: proOmpA* complex formation. proOmpA*$_1$ (5 μM; lane 9) was incubated (50 μl; Buffer C; < 0.2 M urea; 37°C; 60 min) with the indicated molar excess of TF_2 (lanes 3-8). Soluble proteins (20,000 x g; 10 min; 4°C) were analyzed on 10% Native-PAGE (4 mA; 16h; 4°C) and Coomassie-blue stained. Lane 2: max TF amount used. Representative experiment is shown; *n*= 4 biological replicates

F. SecB does not form stable complex with proOmpA*. proOmpA*$_1$ was incubated with the indicated molar excess of $SecB_4$ and soluble proteins analyzed as in E. Lane 2: max SecB amount used. Representative experiment is shown; *n*= 4 biological replicates

G. TF: proOmpX complex formation. proOmpX$_1$ was incubated with the indicated molar excess of TF_2 and soluble proteins analyzed as in E Lane 2: max TF amount used. Representative experiment is shown; *n*= 4 biological replicates

H. SecB: proOmpX complex formation. proOmpX$_1$ was incubated with the indicated molar excess of $SecB_4$ and soluble proteins analyzed as in E Lane 2: max SecB amount used. Representative experiment is shown; *n*= 2 biological replicates



Appendix Figure S4. TF interaction with either SecB, or SecA wt or SecA(noC-tail) in solution (related to Figures 5 and 6).

ITC analysis of TF_2 (cell) with $SecA_2$ **(A)** $SecB_4$ **(B)** and SecA-ΔC-tail **(C)** in the syringe. Experiments were performed in Buffer H at 25°C using an iTC200 instrument (Malvern). The raw data are shown as an injection profile (top) and the calorimetric binding isotherm (bottom). No measurable K_d derived from these experiments. A representative experiment is shown; *n=3* biological replicates





Appendix Figure S5. Native MS of $SecB_4$ and SecB:proOmpA (related to Figures 4 and 5).
A. $SecB_4$ native-MS analysis at 37°C**.** ESI-mass spectrum and charge state distributions of monomer ($SecB_1$), dimer ($SecB_2$) and tetramer ($SecB_4$) populations are colored in yellow, blue and light pink respectively. The deconvoluted mass spectra of native $SecB_4$ are shown ($SecB_1$: 17187.5 Da; SecB2: 34376.5 Da; $SecB_4$: 68763.5 Da). Representative experiment is shown; *n=3* biological replicates **B**. SecB:proOmpA native-MS analysis at 37oC. ESI-mass spectrum and charge state distributions of different protein populations are shown: proOmpA, ($SecB_4$: proOmpA)$_1$, $SecB_4$ and ($SecB_4$: proOmpA)$_2$ are colored in cyan, violet, light pink and light purple respectively. The deconvoluted mass spectra from different populations of the complexes and the derived stoichiometries are shown (cartoon representation). A representative experiment is shown; *n=3* biological replicates



Appendix Figure S6. The C-tail of SecA is not required for TF-mediated inhibition of translocation *in vivo* and proOmpA translocation and chaperone interaction is chaotrope-independent (related to Figure 6)

A. Growth curves of the *E. coli* BL21-19, a strain thermosensitive for the *secA* gene [1], carrying vector pBAD501 (p15A *ori*, gentamycin^R, *ara* promoter)[2] with either the *secA*(no-Ctail) cloned, or empty, and the pASK IBA 7 plus vector (Col E1 ori, ampicillin^R, *tet* promoter) empty or harbouring the cloned *tig* gene (encoding TF), as indicated. Bacteria were grown in LB at 30°C supplemented with Ampicillin (100μg/ml) and Gentamycin (10μg/ml). When culture OD_{600} reached 0.5, gene expression was induced (AHT; 5 ng/ml; L-arabinose; 0.1%w/v), cultures were transferred at 42°C and culture density was determined every 30 minutes post-induction spectrophotometrically. Mean values with SEM are shown; *n*= 3 biological replicates

B. *In vitro* translocation of proOmpA and chaperone effects are independent of chaotrope effects. [^{35}S]-proOmpA was synthesized *in vitro* using a TnT system in the absence of urea, and after removal of the ribosomes by ultra-centrifugation, was used in an *in vitro* SecA-dependent translocation assay (as in Fig. 5C). A representative autoradiograph is shown; *n=3* biological replicates

Appendix Materials

Appendix Table S1: Bacterial Strains

E. coli strain	Description (gene deleted)	Reference/source
MC4100	*F-araD139 ¢(argF-lac)U169 rpsL150 (StrR) relA1 flbB5301 deoC1 pstF25 rbsR*	P. Genevaux [3-5]
MC4100Δ*secB*	In-frame deletion/replacement of the *secB* gene by the *cat* gene.	P. Genevaux [3,4,6,7]
MC4100Δ*tig*Δ*secB*	In-frame deletion/replacement of the *secB* gene by the *cat* gene. The Δ*tig*::Cm^R allele was moved by bacteriophage P1 transduction into MC4100 and the Cm^R cassette was removed by the FLP recombinase.	P. Genevaux [3,4,6,7]
Lemo21(DE3)	T7 RNA polymerase gene under the control of the *lac*UV5 promoter.	New England BioLabs
BL21.19(DE3)	*secA13 (Am) supF (Ts) trp (Am) zch::Tn10 recA::cat clpA::kan)*	[1]
Tuner (DE3)	*lacZY* deletion mutant of BL21.	Novagen
BL31(DE3)	Non *ts* spontaneous revertant of BL21.19(DE3).	[2]

Appendix Table S2: Plasmids

Genes were cloned in the indicated plasmid vectors using combinations of restriction enzymes (as indicated). Mutations were introduced on genes *via* the QuickChange Site-Directed Mutagenesis protocol (Stratagene-Agilent); templates and primers were as indicated. Restriction enzymes and T4 DNA Ligase were either from Minotech (Greece) or Promega or NEB. For PCR mutagenesis PFU Ultra Polymerase (Stratagene) was used; for gene amplification either Expand High fidelity Polymerase (Roche) or PFU Ultra polymerase (Promega) was used. DpnI was used to cleave the maternal methylated DNA (NEB or Promega). All PCR-generated plasmids were sequenced (Macrogen Europe). Plasmids were stored in DH5α cells

Gene	Uniprot accession number	Plasmid name	Vector	Description/source/reference
Preproteins				
pro*ompA**	P0A910	pIMBB454	pET22b	pro*ompA* gene was amplified from pTY009 using the primers X191 and X193 and inserted into the NdeI-EcoRI sites of pET22b. Mutations and additions (Fig. S3A) were introduced during the making of the construct.
pro*ompA*	P0A910	pLMB1835	pET22b	pro*ompA* gene was amplified from pIMBB1589 (pBADpro*ompA*-*phoA*-His) using primers X191 (Forw NdeI) and X1269 (Rev XhoI) and inserted into same sites of pET22b [8].
pro*phoA Δcys*	P00634	pIMBB977	pET22b	[9]
Mature domains				
ompA	P0A910	pIMBB1386	pET22b	*OmpA* gene was amplified from DH5a strain using primers X558 (Forw NdeI)

				and X1269 (Rev XhoI) and inserted to the same sites of pET22b [8].
Chaperones				
secB	P0AG86	pIMBB1602	pASKIBA7 plus	*secB* gene amplified from pIMBB490 (pET16b*secB*) using primers X1944 (Forw XbaI with RBS) and X1945 (Rev HindIII) and was inserted to the same sites of pASKIBA7plus.
tig	P0A850	pIMBB1605	pASKIBA7 plus	*tig* gene (encodes TF) was amplified from pCold-TF (Takara) using primers X1946 (Forw XbaI with RBS) and X1947 (Rev HindIII) and inserted to the same sites of pASKIBA7plus.
tig(3A) (F44A/R45A/K46A)	P0A850	pLMB2079	pASKIBA7 plus	The 3 mutations (F44A/R45A/K46A) were introduced in pIMBB1605 using primer pair X2324-X2325
tig(4A) (M374A/Y378A/V384A/F387A)	P0A850	pIMBB1606	pASKIBA7 plus	*tig* 4A gene amplified from pLMB0038 [10] using primers X1946 and X1947 and was inserted to the XbaI-HindIII sites of pASKIBA7plus.
tig(4A,3A) (F44A/R45A/K46A/ M374A/Y378A/ V384A/F387A)	P0A850	pLMB2080	pASKIBA7 plus	The 3 mutations (F44A/R45A/K46A) were introduced in pIMBB1605 using primer pair X2324-X2325
secB	P0AG86	pIMBB351	pJW25	[11]
tig	P0A850	pCold-TF	pCold-TF	Takara.
Sec Translocase				
secYEG	P0AGA2 P0AG96 P0AG99	pIMBB336	pET610	A. Driessen, University of Groningen, Groningen, the Netherlands [12]
secA(1-901)	P10408	pIMBB10	pET5	[13]
secA(1-834)	P10408	pIMBB1296	pET5	SecA(noC-tail) [14]
secA(1-834)	P10408	pLMB2081	pBAD501	*secA*(noC-tail) gene amplified from pIMBB1296 using primers X157 and X1896 and was inserted to the NdeI-XhoI sites of pBAD501 [2]
secA(1-901)_ PatchA	P10408	pLMB1893	pET3a	SecA(noPatchA) The *secA* N1-314 PatchA/C98S DNA fragment was digested out from sgLMB0060 and inserted to pET3a *secA* 1-901 (pIMBB1280) after NdeI-MluI digestion.
His-*secA* (I304A/L306A)	P10408	pIMBB691	pET5	SecA(noSP) [14]

Appendix Table S3: Primers

X number	**DNA sequence** (5’-3’; Mutated codons are bold, restriction sites underlined)	**Description**
X157	GGCCCGTACATATGCTAATCAAATTGTTAAC	Forward *secA* primer introducing an NdeI site
X191	GGAATTCCATATGAAAAAGACAGCTATCGC	Forward primer for pro*ompA* amplification, introducing an NdeI site.
X193	CGGAATTCTTAAGCCTGCGGCTGAGTTAC	Reverse primer for pro*ompA* amplification, introducing an EcoRI site.
X558	GGGAATTCCATATGGCTCCGAAAGATAACACCT	Forward primer of *ompA* amplification. Anneals at Ala 22 introducing an NdeI 5’ end.
X1269	GACCCGCTCGAGAGCCTGCGGCTGAGTTACAACG	Reverse pro*ompA* primer introducing an XhoI site.
X1896	CCGGACCTCGAGTTATTGCAGGCGGCCATGGCACTGC	Reverse *secA* primer introducing an XhoI site
X1944	GCGGTCTAGATTAAGTATAA**GAAGGAG**ATATACATATGTCAGAACAAAACAACACTG	Forward *secB* primer introducing an rbs region and an XbaI site.
X1945	CCCAAGCTT**TTA**GGCATCCTGATGTTCTTCAGTACCTTC	Reverse *secB* primer introducing a stop codon and a HindIII site.
X1946	GCGGTCTAGATTAAGTATAA**GAAGGAG**ATATACATATGCAAGTTTCAGTTGAAACC	Forward *tig* primer introducing an rbs region and an XbaI site.
X1947	CCCAAGCTT**TTA**CGCCTGCTGGTTCATCAGCTCG	Reverse *tig* primer introducing a stop codon and a HindIII site.
X2324	GCGAAAAAAGTACGTATTGACGGC**GCGGCTGCT**GGCAAAGTGCCAATGAATATCGTT	Forward *tig* primer for generating F44A R45A K46A
X2325	AACGATATTCATTGGCACTTTGCC**AGCAGCCGC**GCCGTCAATACGTACTTTTTTCGC	Reverse *tig* primer for generating F44A R45A K46A

Appendix Table S4: Buffers

Buffer	**Composition**
A	50 mM Tris-HCl pH 8.0; 50 mM NaCl
B	6 M urea; 50 mM Tris-HCl pH 8.0; 50 mM NaCl
C	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 1 mM DTT; 1 mM EDTA
D	50 mM Tris-HCl pH 8.0; 50 mM KCl; 5 mM $MgCl_2$
E	50 mM Tris-HCl; pH 8.0; 50 mM KCl; 5 mM $MgCl_2$; 5 µM $ZnCl_2$; 1mg/ml BSA; 1 mM DTT; 1 mM ATP
F	50 mM Tris-HCl pH 8.0; 50 mM KCl; 1 mM $MgCl_2$; 5 µM $ZnCl_2$
G	50 mM Ammonium Acetate pH 8
H	50 mM Tris HCl pH 7.5, 50 mM NaCl, and 1 mM TCEP
I	50 mM Tris-HCl pH 8.0; 0.5 M NaCl; 10% Glycerol v/v; 5 mM Imidazole; 2.5 mM PMSF; 50 µg/ml DNase I; 1 mM $MgCl_2$
J	50 mM Tris-HCl pH 8.0; 1 M NaCl; 10% Glycerol v/v; 5 mM Imidazole; 2.5 mM PMSF; 50 µg/ml DNase I; 1 mM $MgCl_2$
K	20 mM Tris-HCl pH 7.4; 50mM NaCl; 2.5 mM PMSF; 50 µg/ml DNase I; 1 mM $MgCl_2$
L	50 mM Tris-HCl pH 7.6; 200 mM KCl; 2.5 mM PMSF; 50 µg/ml DNase I; 1 mM $MgCl_2$
M	50 mM Tris-HCl pH 8.0; 20% Glycerol v/v; 10 mg/ml DNase I; 50 mg/ml RNase; 1 mM PMSF
N	50 mM Tris-HCl pH 8.0; 0.5 M NaCl; 10% Glycerol v/v; 8 M urea; 5 mM Imidazole
O	50 mM Tris-HCl pH 8.0; 0.5 M NaCl; 10% Glycerol v/v; 5 mM Imidazole

P	50 mM Tris-HCl pH 8.0; 0.5 M NaCl; 10% Glycerol v/v; 6 M Urea; 5 mM Imidazole
Q	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 10% Glycerol v/v; 6 M Urea; 5 mM Imidazole
R	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 10% Glycerol v/v; 6 M urea; 100 mM Imidazole
S	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 6 M Urea; 10% Glycerol v/v
T	50 mM Tris-HCl pH 8.0; 1 M NaCl; 10% Glycerol v/v; 5 mM Imidazole
U	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 10% Glycerol v/v; 5 mM Imidazole
V	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 10% Glycerol v/v; 100 mM Imidazole
W	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 10% Glycerol v/v
X	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 50% Glycerol v/v
Y	20 mM Tris-HCl pH 7.4; 50 mM NaCl
Z	20 mM Tris-HCl pH 7.4; 100 mM NaCl
AA	20 mM Tris-HCl pH 7.4; 200 mM NaCl
AB	20 mM Tris-HCl pH 7.4; 350 mM NaCl
AC	50 mM Tris-HCl pH 8.0; 1 M NaCl
AD	50 mM Tris-HCl pH 7.6; 200 mM KCl
AE	50 mM Tris-HCl pH 7.6; 1.2 M KCl
AF	50 mM Tris-HCl pH 8.0
AG	50 mM Tris-HCl pH 8.0; 20% Glycerol v/v
AH	6 M Urea; 50 mM Tris-HCl pH 8.0
AI	50 mM Tris-HCl pH 8.0; 0.2 M Sucrose
AJ	50 mM Tris-HCl pH 8.0; 50 mM NaCl; 1 mM DTT; 1 mM EDTA; 6 M Urea
AK	0.2 M Sucrose; 1 mg/ml BSA in 50 mM Tris-HCl pH 8.0; 50 mM KCl; 1 mM $MgCl_2$; 5 μM $ZnCl_2$
AL	6 M Urea; 25 mM Tris pH 8.0; 25 mM KCl
AM	25 mM Tris pH 8.0; 25 mM KCl
AN	6 M Urea-d4 (98% atom D); 5 mM DTT; 95.5% (v/v) D_2O
AO	50 mM Tris-DCl corrected pD 8.0; 50 mM KCl; 1 mM $MgCl_2$; 4 μM $ZnSO_4$; 2 mM TCEP

References

1. Mitchell C, Oliver D (1993) Two distinct ATP-binding domains are needed to promote protein export by Escherichia coli SecA ATPase. *Mol Microbiol* **10:** 483-497
2. Chatzi KE, Sardis MF, Tsirigotaki A, Koukaki M, Sostaric N, Konijnenberg A, Sobott F, Kalodimos CG, Karamanou S, Economou A (2017) Preprotein mature domains contain translocase targeting signals that are essential for secretion. *The Journal of cell biology* **216:** 1357-1369
3. Casadaban MJ (1976) Transposition and fusion of the lac genes to selected promoters in Escherichia coli using bacteriophage lambda and Mu. *Journal of molecular biology* **104:** 541-555
4. Ullers RS, Ang D, Schwager F, Georgopoulos C, Genevaux P (2007) Trigger Factor can antagonize both SecB and DnaK/DnaJ chaperone functions in Escherichia coli. *Proc Natl Acad Sci U S A* **104:** 3101-3106
5. Genevaux P, Schwager F, Georgopoulos C, Kelley WL (2002) Scanning mutagenesis identifies amino acid residues essential for the in vivo activity of the Escherichia coli DnaJ (Hsp40) J-domain. *Genetics* **162:** 1045-1053
6. Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG, Court DL (2000) An efficient recombination system for chromosome engineering in Escherichia coli. *Proc Natl Acad Sci U S A* **97:** 5978-5983
7. Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. *Proc Natl Acad Sci U S A* **97:** 6640-6645
8. Tsirigotaki A, Chatzi KE, Koukaki M, De Geyter J, Portaliou AG, Orfanoudaki G, Sardis MF, Trelle MB, Jorgensen TJD, Karamanou S*, et al.* (2018) Long-Lived Folding Intermediates Predominate the Targeting-Competent Secretome. *Structure* **26:** 695-707 e695
9. Gouridis G, Karamanou S, Sardis MF, Scharer MA, Capitani G, Economou A (2013) Quaternary dynamics of the SecA motor drive translocase catalysis. *Mol. Cell* **52:** 655-666
10. Saio T, Kawagoe S, Ishimori K, Kalodimos CG (2018) Oligomerization of a molecular chaperone modulates its activity. *Elife* **7:**
11. Weiss JB, Ray PH, Bassford PJ, Jr. (1988) Purified secB protein of Escherichia coli retards folding and promotes membrane translocation of the maltose-binding protein in vitro. *Proc Natl Acad Sci U S A* **85:** 8978-8982
12. van der Does C, den Blaauwen T, de Wit JG, Manting EH, Groot NA, Fekkes P, Driessen AJ (1996) SecA is an intrinsic subunit of the Escherichia coli preprotein translocase and exposes its carboxyl terminus to the periplasm. *Mol Microbiol* **22:** 619-629
13. Karamanou S, Vrontou E, Sianidis G, Baud C, Roos T, Kuhn A, Politou AS, Economou A (1999) A molecular switch in SecA protein couples ATP hydrolysis to protein translocation. *Mol Microbiol* **34:** 1133-1145
14. Gelis I, Bonvin AM, Keramisanou D, Koukaki M, Gouridis G, Karamanou S, Economou A, Kalodimos CG (2007) Structural basis for signal-sequence recognition by the translocase motor SecA as determined by NMR. *Cell* **131:** 756-769